TECHNETIUM TC-99M TROFOLASTAT CHLORIDE

drug
On this page

Also known as 99mtc-mip-1404Cloruro de tecnecio (99mtc) trofolastatF-1311MIP TC-1404MIP-99MTC-1404Technetium (99mtc) trofolastat chlorideTechnetium tc 99m trofolastat chloride

Summary

Technetium Tc-99M Trofolastat Chloride (CHEMBL4297855) is a phase-3 clinical-stage unknown (ATC V09IA10).

At a glance

  • Status: Max clinical phase 3 (not approved)
  • Modality: Unknown
  • ATC class: V09IA10
  • Clinical trials: 4

Identifiers

Drug identity and classification

FieldValue
ChEMBL IDCHEMBL4297855
NameTECHNETIUM TC-99M TROFOLASTAT CHLORIDE
TypeUnknown
Max phase3
ATCV09IA10

Also known as: 99mtc-mip-1404, Cloruro de tecnecio (99mtc) trofolastat, F-1311, MIP TC-1404, MIP-99MTC-1404, Technetium (99mtc) trofolastat chloride, Technetium tc 99m trofolastat chloride, Technetium tc-99m trofolastat chloride, TECHNETIUM TC-99M TROFOLASTAT CHLORIDE

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 4.

Phase distribution

PhaseTrials
PHASE12
PHASE31
PHASE21

Top trials by phase / activity

NCTPhaseStatusTitle
NCT02615067PHASE3COMPLETEDStudy to Evaluate 99mTc-MIP-1404 SPECT/CT Imaging in Men With Biopsy Proven Low-Grade Prostate Cancer
NCT01667536PHASE2COMPLETEDA Phase 2 Study With MIP-1404 in Men With High-Risk PC Scheduled for RP and EPLND Compared to Histopathology
NCT01572701PHASE1COMPLETEDPilot Study of 99mTc-MIP-1404 SPECT/CT Imaging in Men With Prostate Cancer Undergoing Prostatectomy and/or Pelvic Lymph Node Dissection
NCT01654874PHASE1COMPLETED99mTc-MIP-1404 for Imaging Prostate Cancer: Phase I Clinical Study to Assess the Image Quality of a Simplified Kit Formulation Compared to a Multi-step Preparation of 99mTc-MIP-1404

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).

No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.